SCHEMBL1879575

SCHEMBL1879575

C=CCCC(F)(F)C(=O)OCC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PKM P14618 3/20 0.36
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
THRB P10828 1/20 0.36
HTT P42858 1/20 0.35
MAPT P10636 2/20 0.35
HIF1A Q16665 1/20 0.35
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
POLB P06746 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 2/20 0.32
HSD17B10 Q99714 1/20 0.32
ALOX15 P16050 1/20 0.31
MGAM O43451 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14639270 0.91 CYP4F2 (0.39) MAPK1MEN1KMT2APKMCYP4F2
SCHEMBL13292651 0.82 MAPK1 (0.39) MAPK1MEN1KMT2APKMCYP4F2
SCHEMBL7758971 0.81 MEN1 (0.52) MAPK1MEN1KMT2APKMCYP4F2
SCHEMBL1226141 0.81 MAPK1 (0.39) MAPK1MEN1KMT2APKMCYP4F2
SCHEMBL24241314 0.81 POLB (0.46) MAPK1MEN1KMT2APKMCYP4F2
SCHEMBL3251799 0.79 CYP4F2 (0.53) MAPK1MEN1KMT2APKMCYP4F2
SCHEMBL6067617 0.79 MMP8 (0.42) MAPK1MEN1KMT2APKMCYP4F2
SCHEMBL24565358 0.79 MEN1 (0.38) MAPK1MEN1KMT2APKMCYP4F2
SCHEMBL27351976 0.78 FAAH (0.46) MAPTALDH1A1LMNAHSD17B10ALOX15
SCHEMBL14533806 0.78 MEN1 (0.42) MEN1KMT2APKMCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102525-A1 COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF SILBER B MICHAEL (US) 2026-04-16 US disclosed
US-20250255992-A1 COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF REILEY PHARMACEUTICALS INC (US) 2025-08-14 US disclosed
US-20240358866-A1 NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING REILEY PHARMACEUTICALS INC (US) 2024-10-31 US disclosed
WO-2024118818-A1 NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING Reiley Pharmaceuticals, Inc. (US) 2024-06-06 WO disclosed
EP-4225384-A1 COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF Reiley Pharmaceuticals, Inc. (US) 2023-08-16 EP disclosed
CN-116406368-A Conjugated compounds derived from sibs and methods of use thereof 赖利制药公司 2023-07-07 CN disclosed
US-20220133918-A1 COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF Reiley Pharmaceuticals, Inc. 2022-05-05 US disclosed
US-20220133918-A1 COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF Reiley Pharmaceuticals, Inc. 2022-05-05 US disclosed
US-7947683-B2 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors GLAXO GROUP LIMTED (GB) 2011-05-24 US disclosed
US-7947683-B2 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors GLAXO GROUP LIMTED (GB) 2011-05-24 US disclosed
US-7947683-B2 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors GLAXO GROUP LIMTED (GB) 2011-05-24 US disclosed
US-20090124629-A1 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2009-05-14 US disclosed
US-20090124629-A1 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2009-05-14 US disclosed
US-20090124629-A1 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2009-05-14 US disclosed
EP-1869017-A1 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2007-12-26 EP disclosed
WO-2006108701-A1 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124629-A1 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS DRD3, HTR3C, TACR2 MAPK1 1400/4885MEN1 3837/4885KMT2A 4062/4885
US-20250255992-A1 COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF PTGES2, PTGES, OPRK1 MAPK1 1538/4885MEN1 4012/4885KMT2A 3427/4885
US-20260102525-A1 COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF OPRK1, OPRD1, OPRM1 MAPK1 1027/4885MEN1 1470/4885KMT2A 2292/4885
US-20220133918-A1 COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF PTGES2, PTGES, OPRK1 MAPK1 1538/4885MEN1 4012/4885KMT2A 3427/4885
US-20240358866-A1 NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING PTGES2, PTGS2, PTGES MAPK1 1753/4885MEN1 3431/4885KMT2A 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.